IGF1R and Ewing sarcoma: Because Ewing sarcoma has been shown to have susceptibility to IGF1R inhibitors, with modest activity observed in clinical trials [51], this novel combination may prove interesting in Ewing sarcoma and will be the focus of future investigation.